Magenta Therapeutics Inc represents a commitment to transformative science in the field of cellular and gene therapies. The company focuses on developing novel medicines to revolutionize the treatment of severe diseases, such as autoimmune disorders, blood cancers, and genetic diseases. Magenta Therapeutics is guided by a patient-centric approach, aiming to provide life-changing therapies that address significant unmet medical needs. The company's corporate philosophy embraces collaboration, innovation, and expertise to accelerate the development of breakthrough therapies. With a focus on precision medicine, Magenta Therapeutics envisions a future where patients can benefit from personalized, curative treatments that improve their quality of life.

Magenta Therapeutics Inc is primarily present in the United States.

Magenta Therapeutics Inc has achieved significant milestones in its journey. The company successfully completed its initial public offering (IPO) in June 2018, raising approximately $100 million in proceeds. Since then, Magenta Therapeutics Inc has made considerable progress in advancing its innovative platform focused on harnessing stem cell biology to develop curative therapies. The company has established strategic partnerships with leading institutions, including the National Institutes of Health (NIH), to accelerate the development of its products. Magenta Therapeutics Inc has also initiated clinical trials for its candidates, aiming to address critical unmet needs in stem cell transplant and gene therapy. These achievements highlight the company's commitment to revolutionizing the field of regenerative medicine.

Magenta Therapeutics Inc is a leading biotechnology company specializing in developing transformative medicines for patients with debilitating diseases. Founded in 2016, the company has quickly made significant strides in the field of regenerative medicine. Magenta Therapeutics aims to revolutionize stem cell transplantation by harnessing the power of stem cells to deliver curative therapies for blood and immune system diseases, such as multiple sclerosis, leukemia, and certain genetic disorders. With its cutting-edge research, novel technologies, and strategic partnerships, Magenta Therapeutics is at the forefront of advancing the field of regenerative medicine, providing hope for patients in need of life-changing treatments.

The main competitors of Magenta Therapeutics Inc in the market include other companies operating in the field of biotechnology and cell therapy. Some prominent competitors of Magenta Therapeutics Inc may include companies like bluebird bio, Novartis AG, CRISPR Therapeutics, and Sangamo Therapeutics, among others. These companies also focus on developing innovative therapies and technologies for various indications, potentially competing with Magenta Therapeutics Inc in the pursuit of breakthrough treatments.

Magenta Therapeutics Inc is primarily active in the biotechnology industry.

Magenta Therapeutics Inc's business model revolves around developing innovative therapies for patients with autoimmune diseases, blood cancers, and genetic diseases through the use of stem cell transplantation. The company focuses on harnessing the power of stem cell biology and gene editing technologies to create durable and curative treatments. Magenta Therapeutics Inc aims to provide patients with safer and more effective therapies by improving the transplantation process and reducing the need for toxic treatments. The company's research and development efforts are dedicated to advancing clinical pipeline candidates and expanding the potential applications of stem cell transplantation in various disease areas.

Pomer Magenta Therapeutics cena/zisk je 564,19.

Koeficient Magenta Therapeutics P/S je 0.

AlleAktien kvalitatívne skóre pre Magenta Therapeutics je 1/10.

Aktuálne nie je možné vypočítať obrat pre Magenta Therapeutics.

Zisk očakávaná Magenta Therapeutics je 1,24 mil. USD.

Magenta Therapeutics is a biopharmaceutical company based in Cambridge, USA, focused on developing innovative therapies for life-threatening diseases. The company utilizes proprietary stem cell transplantation technology to expand the potential of hematopoietic stem cells (HSCs) for treating serious illnesses. The business model of Magenta Therapeutics is based on developing products for stem cell transplantation, allowing doctors and patients to treat rare diseases. The company operates in four main areas: research and development, manufacturing, clinical trials, and marketing. Magenta Therapeutics' research and development department is responsible for identifying and developing new therapy approaches based on HSCs. The company has an extensive portfolio of proprietary technologies and IP positions, including a groundbreaking gene editing technology that enables targeted manipulation of specific cells in the body. In the manufacturing sector, Magenta Therapeutics operates its own facility for stem cell processing and isolation. The company has also partnered with other manufacturing companies to support the production of stem cells for clinical trials and patient treatments. Magenta Therapeutics' clinical divisions conduct clinical trials to evaluate the effectiveness and safety of products for stem cell transplantation. The company has conducted several clinical studies and plans to conduct more in the near future. Finally, Magenta Therapeutics also has its own marketing department responsible for promoting products for stem cell transplantation. The company has agreements with insurers, hospitals, and clinics to facilitate patient access to its products. Magenta Therapeutics has focused on developing three main products targeting stem cell transplantation. The first product is a gene therapy approach called MGTA-456, which selectively manipulates HSCs to improve engraftment rates and patient survival after stem cell transplantation. The second product is a therapy called MGTA-117, which stimulates the growth of HSCs in the blood and promotes red blood cell production. MGTA-117 has the potential to revolutionize the treatment of patients with anemia and other hematological diseases. Finally, Magenta Therapeutics is also developing a third product called MGTA-145, which aims to use HSCs for treating autoimmune diseases. MGTA-145 has the potential to improve the treatment of patients with severe autoimmune diseases such as multiple sclerosis. In summary, Magenta Therapeutics' business model is focused on developing innovative stem cell transplantation products to help patients with serious illnesses. The company has extensive expertise in researching, developing, manufacturing, and marketing stem cell products and has a portfolio of proprietary technologies and IP positions that differentiate it from other companies in the industry.

Magenta Therapeutics vypláca dividendu vo výške 0 USD rozdelenú do výplat počas roka.

Dividenda pre Magenta Therapeutics sa aktuálne nedá vypočítať alebo spoločnosť nevypláca dividendu.

ISIN spoločnosti Magenta Therapeutics je US55910K1088.

WKN spoločnosti Magenta Therapeutics je A2JPD6.

Ticker spoločnosti Magenta Therapeutics je MGTA.

V posledných 12 mesiacoch spoločnosť Magenta Therapeutics vyplatila dividendu vo výške . To zodpovedá dividendovému výnosu približne . Pre nadchádzajúcich 12 mesiacov bude pravdepodobne spoločnosť Magenta Therapeutics vyplácať dividendu 0 USD.

Súčasný výnos z dividend spoločnosti Magenta Therapeutics je .

Magenta Therapeutics vypláca dividendu každý štvrťrok. Tá je vyplácaná v mesiacoch .

Magenta Therapeutics platil každý rok počas posledných 0 rokov dividendu.

Na nasledujúcich 12 mesiacov sa očakávajú dividendy vo výške 0 USD. To zodpovedá dividendovému výnosu 0 %.

Magenta Therapeutics je priradený sektoru 'Zdravie'.

Aby ste obdržali poslednú dividendu vo výške 0 USD od Magenta Therapeutics z dňa 17. 8. 2024, museli ste mať akciu v depozite pred ex-dňom 17. 8. 2024.

Posledná dividenda bola vyplatená 17. 8. 2024.

V roku 2023 boli od Magenta Therapeutics 0 USD vyplatené ako dividendy.

Dividendy spoločnosti Magenta Therapeutics sú vyplácané v USD.